Macrophage Pharma is developing a highly novel class of small molecule therapeutics which modulate immune responses to combat cancer based on its proprietary Esterase Motif Technology™ (ESM™) platform. ESM molecules deliver small molecule inhibitors of key intracellular targets in a highly selective manner to macrophages, monocytes and monocyte-derived dendritic cells. Macrophage Pharma is rapidly progressing its lead molecules to the clinic utilising ESM to deliver inhibitors to tumour associated macrophages and tolerogenic dendritic cells in the tumour microenvironment.
The Company was founded by the CRT Pioneer Fund and recently announced a £9 million financing round. The round was led by CPF who were joined by two specialist investors, Novo A/S and Aglaia Biomedical Ventures BV. The proceeds of the financing round will enable the Company to complete the pre-clinical development of its lead development candidate, a p38 MAP kinase inhibitor, and advance two additional discovery candidates into pre-clinical development.
The company’s management team has track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of our unique approach in immuno-oncology.